| | Patient | At diagnosis | Prior treatment | CNS presentation | Survival (days) | | Age | Sex | ISS/PCL | FISH/karyotype | M-protein | Lines | Thal | Bor | Len | ASCT | Age | Symptoms | Diagnosis | Systemic relapse | ISS | New FISH | Treatment | Response | OS from CNS | OS from DG | PFS from CNS | DG to CNS |
| | 1 | 69 | M | 3 | 1q amp | LC lambda | 1 | 1 | 1 | 0 | 0 | 69 | Double vision | CT, CSF flow | yes | 3 | ND | EDAP, IT, Mel-ASCT, Len maint | PR | 144 | 335 | 130 | 191 | | 2 | 65 | M | 1 | 1q amp | LC kappa | 1 | 0 | 1 | 0 | 0 | 65 | Paraplegia | CSF flow | yes | 1 | ND | VTD, Mel-ASCT, Len maint | PR | 427 | 897 | 124 | 470 | | 3 | 69 | F | 1 | ND | IgG lambda | 2 | 1 | 1 | 0 | 0 | 74 | Double vision | CSF IFX | no | 1 | ND | LenDex | NR | 56 | 2025 | 0 | 1969 | | 4 | 41 | F | 3 | 1q amp | LC lambda | 1 | 1 | 1 | 0 | 0 | 41 | Headache, hypoglossus, and abducent paresis | Clinical (unspecific MRI abnormalities) | yes | 3 | 17p | VRD-PACE, IT, EDAP, IRD, Mel-Benda-ASCT | PR | 180 | 290 | 63 | 110 | | 5 | 52 | M | 3 | del 13q | IgA kappa | 3 | 1 | 1 | 0 | Allo | 55 | Abducent paresis, unable to swallow | CSF cytospin, MRI | no | 1 | ND | Thal + IT + craniocaudal irrad + discontinue GVHD prophylaxis | CR | 134 | 1103 | 126 | 969 | | 6 | 56 | F | 3 | hyperd | IgA kappa | 3 | 1 | 1 | 0 | 1 | 60 | Headache | MRI | no | 1 | ND | Thal + craniocaudal irrad, benda-VTD | PR | 776 | 2191 | 104 | 1415 | | 7 | 54 | M | 3 | del 13q | IgA kappa | 2 | 1 | 1 | 0 | 1 | 56 | Oculomotor nerve paresis | Clinical (MRI orbit neg, CSF ND) | yes | 3 | 1qamp | VTD | NR | 93 | 1033 | 32 | 940 | | 8 | 53 | M | 3 | complex, hypodipl | IgG lambda | 3 | 1 | 1 | 0 | 2 | 57 | Abducent paresis | Clinical (MRI neg, CSF ND) | yes | 3 | same | PAD-Thal | MR | 213 | 1563 | 210 | 1350 | | 9 | 43 | M | 3, PCL | complex, del 13q | LC lambda | 1 | 0 | 1 | 0 | 0 | 44 | Paresis, cannot swallow | CSF cytospin, MRI: tumors | yes | 3 | same | HD MTX, AraC, IT | PD | 44 | 140 | 0 | 96 | | 10 | 66 | M | 3 | 1q amp | IgG lambda | 2 | 1 | 1 | 0 | 0 | 67 | Abducent paresis | MRI | yes | 3 | same | IRD | PD | 14 | 386 | 0 | 372 | | 11 | 34 | M | 2 | t(4;14) | IgG lambda | 3 | 1 | 1 | 1 | 1 | 36 | Left leg paresis | MRI, CSF flow | yes | 1 | same | Thio, Car, Thal, Dex | PR | 38 | 557 | 38 | 519 | | 12 | 60 | F | 3, PCL | t(11;14), del 17p | IgG kappa | 2 | 1 | 1 | 1 | 1 | 60 | Seizures | CSF cytospin | yes | 3 | same | VTD-PACE + ith triplet 4x, Mel-TBI allo | PD | 110 | 325 | 0 | 215 | | 13 | 72 | M | 2 | normal | LC kappa | 4 | 1 | 1 | 1 | 0 | 73 | Back pain | CSF flow, CT | yes | ND | 1qamp | DVd + IT | PR | 60 | 695 | 60 | 675 |
| | Mean | 56.5 | | | 8/12 HR | 7/13 lambda | 2 | | | | | 58.2 | | | | | | | | 125 | 897 | 63 | 715 |
|
|
Allo: allogeneic stem cell transplantation; amp: amplification; ASCT: autologous stem cell transplantation; Bor: bortezomib; Car: carfilzomib; CI: cranial irradiation; CSF: cerebrospinal fluid; CTD: cyclophosphamide, thalidomide, and dexamethasone; CyBorDex: cyclophosphamide, bortezomib, and dexamethasone; Dara: daratumumab; del: deletion; DVd: daratumumab, bortezomib, and dexamethasone; flow: flow cytometry; hyperd: hyperdiploid; IFX: immunofixation; IRD: ixazomib, revlimid, and dexamethasone; IT: intrathecal chemotherapy; KTD: carfilzomib, thalidomide, and dexamethasone; LC: light chain; Len: lenalidomide; maint: maintenance; MPV: melphalan, prednisolone, and bortezomib; ND: not done; PACE: cisplatin, doxorubicin, cyclophosphamide, and etoposide; PAD: bortezomib, doxorubicin, and dexamethasone; PCL: plasma cell leukemia; PomD: pomalidomide and dexamethasone; RT: radiotherapy; T-CED: thalidomide, cyclophosphamide, etoposide, and dexamethasone; Thal: thalidomide; Thio: thiotepa; VAD: vincristine, doxorubicin, and dexamethasone; VTD: bortezomib, thalidomide, and dexamethasone.
|
